|
Insulin Resistance Atherosclerosis Study (IRAS) Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Insulin Resistance Atherosclerosis Study (IRAS) conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Insulin Resistance Atherosclerosis Study (IRAS) Clinical research trials and Insulin Resistance Atherosclerosis Study (IRAS) health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Insulin Resistance Atherosclerosis Study (IRAS). Insulin Resistance Atherosclerosis Study (IRAS) Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Insulin Resistance Atherosclerosis Study (IRAS) clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Insulin Resistance Atherosclerosis Study (IRAS) condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Insulin Resistance Atherosclerosis Study (IRAS)  Insulin Resistance Atherosclerosis Study (IRAS)
Insulin Resistance Atherosclerosis Study (IRAS)
For Condition: Heart Diseases,Insulin Resistance,Atherosclerosis,Obesity,Cardiovascular Diseases,Diabetes Mellitus
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To conduct a multicenter study of the relationship between insulin resistance and cardiovascular disease (CVD) and its risk factors in a tri-ethnic (African-American, Hispanic, and non-Hispanic white) population aged 40 to 69 years at baseline. Also, to identify the genetic determinants of insulin resistance and visceral adiposity.
Details: BACKGROUND: An association between overt diabetes and cardiovascular disease has been observed in multiple studies among populations across the world. The reason for this excess are only partly understood. In recent years, several studies have suggested that elevations in levels of insulin or insulin resistance are important risk factors for cardiovascular disease, not only in diabetic patients but also among those with normal or subclinical abnormalities in glucose tolerance. Many reasons exist to investigate the role of insulin and insulin resistance in the development of cardiovascular disease. Insulin has effects on multiple metabolic pathways and has been shown to promote development of atherosclerotic lesions in animals. In addition, levels of insulin and insulin resistance are correlated with multiple abnormalities in other cardiovascular disease risk factors such as elevations in blood pressure, dyslipidemia, and alterations in coagulation factors. It is particularly important to determine whether these associations are strongest with levels of insulin or of insulin resistance since this information will be valuable both for studies aimed at localizing the site of the defect and in developing new therapeutic interventions. Despite evidence from population studies, it is difficult to explain the excess of cardiovascular disease in diabetics solely as a consequence of elevations in insulin levels. Recent, small studies suggest that the risk previously associated with hyperinsulinemia may be correlated more strongly with increases in insulin resistance. Insulin resistance continues to increase as glucose levels increase, even in the presence of decreasing insulin secretion. Such observations may help to explain the higher risk of cardiovascular disease in overt diabetics. More detailed assessments of the role of insulin resistance in altering cardiovascular disease risk factors are also needed. Prior to the IRAS study, direct measures of insulin resistance had not been performed in population studies. The continuation of IRAS for an additional five years will provide the first longitudinal data on insulin resistance as a cardiovascular disease risk factor. The IRAS was proposed by staff and approved by the Clinical Applications and Prevention Advisory Committee in May, 1990. The Request for Applications was released in November, 1990. Awards were first made in September, 1991. The study was extended for an additional five years in September, 1995 and in August, 1999. DESIGN NARRATIVE: The study population was selected to insure adequate numbers of participants within gender and glucose tolerance groups (normoglycemia, impaired glucose tolerance, and non-insulin dependent diabetes mellitus). IRAS is the first large epidemiologic study to include detailed measurements of insulin sensitivity and secretion. During the first four years of funding, the IRAS investigators successfully designed and implemented the first phase of the study--a cross-sectional evaluation of 1,625 participants. Cohort examinations began in October, 1992 and were completed in April, 1994. Insulin resistance was assessed directly using the frequently sampled intravenous glucose tolerance test with minimal model analysis. Intimal-medial carotid artery wall thickness, an indicator of atherosclerosis, was measured using B-mode ultrasonography. Prevalent cardiovascular disease was assesed by questionnaire and resting electrocardiograpy. The IRAS was renewed in September, 1995 for an additional five years through July, 1999 for the prospective follow-up and reexamination of the cohort. The renewal period consisted of three phases. During the first phase (years 05 and 06), the investigators conducted a substudy to address the measurement of insulin sensitivity in individuals with NIDDM. This substudy evaluated several alternate techniques for measuring insulin sensitivity in approximately 115 non-IRAS volunteers with NIDDM. In addition, all IRAS participants were contacted annually for incident cardiovascular and other major health events. During the second phase (years 07 and 08), a follow-up examination of the IRAS cohort was conducted with the goal of determining predictors of changes in insulin sensitivity, cardiovascular risk factors, measures of atherosclerosis development, and incident cardiovascular events. Additionally, throughout the first four years, there was a continued major effort devoted to the analysis and reporting of the cross-sectional data from the first IRAS examination. The final phase (year 09) included analysis and reporting of the longitudinal results. Since existing measures of insulin resistance do not appear to measure exactly the same thing, substudies have been conducted to compare insulin resistance measurement techniques and enable the IRAS data to be related to other studies in the literature. A decision has been made to continue the frequently sampled intravenous glucose tolerance test (FSIGT) as the vascular resistance measure in the IRAS. The FSIGT is compared with other measures of insulin resistance in diabetics. The IRAS was renewed in August 1999 through July 2004 as the IRAS Family Study. The purpose is to identify the genetic determinants of insulin resistance and abdominal obesity and to determine the extent to which insulin resistance, visceral adiposity, and metabolic cardiovascular disease risk factors share common genetic influences. Families of African-American and Hispanic background will be enrolled using participants of the original IRAS study as index cases. Approximately 1,280 additional family members will be recruited to the study for a total of 1,440 participants. Insulin resistance will be measured using the frequently sampled intravenous glucose tolerance test, and abdominal obesity will be measured using computed tomography. Metabolic cardiovascular disease risk factors will also be assessed. A panel of 370 micro satellite markers will be genotyped to provide data for a genome-wide scan to detect chromosomal regions containing quantitative trait loci (QTLs) that influence phenotypic variation for insulin resistance and visceral adiposity.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RichardBergman, , University of Southern California
Additional Information:
Study ID Numbers: 1005;
Study Start Date: September 1991
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005135
Other Insulin Resistance Studies:
1. Magnetic Resonance Imaging to Detect Blood Vessel Inflammation in Patients Undergoing Peripheral Balloon Angioplasty
2. Epidemiology of Coronary Artery Calcification
3. Epidemiology of Carotid Disease in Elderly Adults
4. Racial Differences in Control of Blood Vessel Tone and Blood Flow
5. Cholesterol Reduction in Seniors Program (CRISP)
Related Studies:
Other Insulin Resistance Clinical Trials
Other Clinical Trials
Other Clinical Trials
Insulin Resistance Atherosclerosis Study (IRAS)
|
|
|
|
|
|
|
|
